$0.96 EPS Expected for Eagle Pharmaceuticals Inc (EGRX) This Quarter

Share on StockTwits

Wall Street brokerages expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to post earnings per share of $0.96 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.85 and the highest estimate coming in at $1.06. Eagle Pharmaceuticals posted earnings per share of $1.00 in the same quarter last year, which would suggest a negative year over year growth rate of 4%. The company is scheduled to report its next quarterly earnings report on Monday, February 25th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.72 per share for the current financial year, with EPS estimates ranging from $3.51 to $3.92. For the next year, analysts anticipate that the firm will report earnings of $4.42 per share, with EPS estimates ranging from $4.12 to $4.98. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.27. The business had revenue of $51.34 million for the quarter, compared to analysts’ expectations of $52.70 million. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. The business’s quarterly revenue was down 18.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 EPS.

A number of analysts have recently weighed in on the company. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. TheStreet upgraded Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Cantor Fitzgerald cut Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 1st. Finally, Piper Jaffray Companies set a $88.00 target price on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $77.17.

Shares of Eagle Pharmaceuticals stock traded down $1.46 on Monday, reaching $50.49. 243,800 shares of the company were exchanged, compared to its average volume of 245,806. The company has a current ratio of 5.59, a quick ratio of 5.38 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $774.73 million, a price-to-earnings ratio of 14.98 and a beta of 1.72. Eagle Pharmaceuticals has a 1-year low of $46.88 and a 1-year high of $85.66.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY boosted its stake in Eagle Pharmaceuticals by 22.4% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 3,513 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 642 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Eagle Pharmaceuticals by 33.5% during the 3rd quarter. State of Alaska Department of Revenue now owns 3,607 shares of the specialty pharmaceutical company’s stock valued at $250,000 after purchasing an additional 905 shares in the last quarter. MetLife Investment Advisors LLC boosted its stake in Eagle Pharmaceuticals by 22.5% during the 2nd quarter. MetLife Investment Advisors LLC now owns 4,988 shares of the specialty pharmaceutical company’s stock valued at $377,000 after purchasing an additional 915 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in Eagle Pharmaceuticals by 32.4% during the 3rd quarter. Louisiana State Employees Retirement System now owns 4,900 shares of the specialty pharmaceutical company’s stock valued at $340,000 after purchasing an additional 1,200 shares in the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Read More: What is the 52-week high/low?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply